Compare Bristol-Myers Squibb Co (BMY) vs Burlington Stores Inc (BURL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Burlington Stores Inc — how do they compare? Bristol-Myers Squibb Co trades at $63.79 (market cap $129.94B), while Burlington Stores Inc trades at $353.61 (market cap $22.59B). The key difference: Bristol-Myers Squibb Co is far larger — about 5.8× Burlington Stores Inc's market cap, and Bristol-Myers Squibb Co pays a 3.96% dividend while Burlington Stores Inc pays none. Which is the better fit depends on your goals.
| BMY | BURL | |
|---|---|---|
Market Cap | $129.94B | $22.59B |
Sector | Health | Consumer Cyclical |
52-Week High | $65.89 | $372.19 |
52-Week Low | $42.60 | $242.43 |
Enterprise Value | $163.92B | $27.71B |
Dividend Yield | 3.96% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $63.83, down 1.56% today, with strong technical bullish signals and consistent earnings beats. The stock shows robust fundamentals with a 14.01 P/E ratio, 18.87% net margin, and recent $2.3 billion manufacturing investment. Analyst consensus leans neutral with a $68.56 price target, while technical indicators suggest bullish momentum with key support at $63.
BMY presents a balanced opportunity with strong profitability and growth pipeline offset by patent expiration risks. The stock's current valuation appears reasonable with upside potential to analyst targets, though investors should monitor debt levels and competitive pressures in the pharmaceutical sector.
Burlington Stores (BURL) trades at $351.88, down 5.28% today but maintains strong technical support near $352. The company demonstrates robust fundamentals with revenue growth from $10.63B to $11.9B projected for 2026, net income margin expansion to 5.23%, and consistent earnings beats. Recent news highlights successful smaller-store strategy execution and multiple analyst upgrades. Technical indicators show a bullish moving average signal while oscillators remain neutral, with key support at $352 and resistance at $365.
BURL presents a compelling growth story with 94% analyst buy ratings and a $367 consensus target offering 4.3% upside. The retailer's margin expansion and store productivity improvements drive optimism, though competitive pressures and consumer spending sensitivity pose risks. Institutional ownership trends show mixed activity with recent insider selling offset by fund position increases.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Burlington Stores Inc
Burlington is a leading off-price retailer in the US, offering branded apparel, footwear, and home goods at significant discounts. It operates hundreds of stores focused on delivering high-quality products at great value.
Read more on BURL →
